UA27298U - Method for preventing pleural empyema after pneumonectomy - Google Patents

Method for preventing pleural empyema after pneumonectomy

Info

Publication number
UA27298U
UA27298U UAU200706605U UAU200706605U UA27298U UA 27298 U UA27298 U UA 27298U UA U200706605 U UAU200706605 U UA U200706605U UA U200706605 U UAU200706605 U UA U200706605U UA 27298 U UA27298 U UA 27298U
Authority
UA
Ukraine
Prior art keywords
stump
tienam
pleural
solution
dissected
Prior art date
Application number
UAU200706605U
Inventor
Yurii Ivanovych Feschenko
Vasyl Mykhailovych Melnyk
Mykola Stepanovych Opanasenko
Oleksandr Daliievych Stashenko
Oleksandr Volodym Tereshkovych
Maksym Ivanovych Babych
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to UAU200706605U priority Critical patent/UA27298U/en
Publication of UA27298U publication Critical patent/UA27298U/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for preventing the pleural empyema after pneumonectomy provides for the separation of the principal bronchus sparing maximally surrounding fat with the vascular and nervous plexus. The mucosa is dissected from the distal part of the bronchial stump. Additional ligatures are applied to stump angles involving surrounding tissues. Tienam powder is applied to bronchus section where the non-sterile mucosa was dissected and to the anterior and posterior lips of the stump. Then Tachocomb plate is applied until its complete adhesion. Tienam powder (0.5 g) is applied followed by the pleurization of the bronchial stump generating the dublicature of the pleural leaves. The pleural cavity is sanitized mechanically and chemically with Cyprofloxacin solution. Starting from the second day, the pleural cavity is filled with the isotonic solution with the aid of microirrigator for three days. Tienam (1.0 g in 100 mL of Metronidasol solution) isadministered for five days in the morning while in the evening 1.0 g of Amicacin is employed. Finally, an antibiotic is prescribed based on the assessment of the susceptibility of the plated bacteria.
UAU200706605U 2007-06-13 2007-06-13 Method for preventing pleural empyema after pneumonectomy UA27298U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU200706605U UA27298U (en) 2007-06-13 2007-06-13 Method for preventing pleural empyema after pneumonectomy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU200706605U UA27298U (en) 2007-06-13 2007-06-13 Method for preventing pleural empyema after pneumonectomy

Publications (1)

Publication Number Publication Date
UA27298U true UA27298U (en) 2007-10-25

Family

ID=39017055

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU200706605U UA27298U (en) 2007-06-13 2007-06-13 Method for preventing pleural empyema after pneumonectomy

Country Status (1)

Country Link
UA (1) UA27298U (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2540166C1 (en) * 2013-09-04 2015-02-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кабардино-Балкарский государственный университет им. Х.М. Бербекова" (КБГУ) Method for bronchial stump closure
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9402845B2 (en) 2005-12-08 2016-08-02 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9827317B2 (en) 2002-10-29 2017-11-28 Insmed Incorporated Sustained release of antiinfectives
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
US10238675B2 (en) 2014-05-15 2019-03-26 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827317B2 (en) 2002-10-29 2017-11-28 Insmed Incorporated Sustained release of antiinfectives
US9549925B2 (en) 2005-12-08 2017-01-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9402845B2 (en) 2005-12-08 2016-08-02 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9511082B2 (en) 2005-12-08 2016-12-06 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US10328071B2 (en) 2005-12-08 2019-06-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9549939B2 (en) 2005-12-08 2017-01-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9737555B2 (en) 2007-05-07 2017-08-22 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US10064882B2 (en) 2007-05-07 2018-09-04 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
US10471149B2 (en) 2012-11-29 2019-11-12 Insmed Incorporated Stabilized vancomycin formulations
RU2540166C1 (en) * 2013-09-04 2015-02-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кабардино-Балкарский государственный университет им. Х.М. Бербекова" (КБГУ) Method for bronchial stump closure
US10238675B2 (en) 2014-05-15 2019-03-26 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10398719B2 (en) 2014-05-15 2019-09-03 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10251900B2 (en) 2014-05-15 2019-04-09 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10588918B2 (en) 2014-05-15 2020-03-17 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10751355B2 (en) 2014-05-15 2020-08-25 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10828314B2 (en) 2014-05-15 2020-11-10 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US11395830B2 (en) 2014-05-15 2022-07-26 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US11446318B2 (en) 2014-05-15 2022-09-20 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US12016873B2 (en) 2014-05-15 2024-06-25 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Similar Documents

Publication Publication Date Title
UA27298U (en) Method for preventing pleural empyema after pneumonectomy
GB2468811A (en) Methods and devices for intraoral tactile feedback
MX2007004111A (en) Salt and crystalline forms thereof of a drug.
EP2322600A3 (en) Cultured three dimensional tissues and uses thereof
MY158100A (en) 6,9-disubstituted purine derivatives and their use for treating skin
WO2006116353A8 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
SG152226A1 (en) Methods for treating bone cancer pain by administering a nerve growth factor antagonist
NZ596244A (en) Treatment of neurodegenerative diseases
BRPI0718114A2 (en) method for stimulating growth factor production by human umbilical cord blood cells, in vitro method for expanding human umbilical cord blood cells, and method for improving survival and growth of transplanted human umbilical cord blood cells in a individual
NZ594698A (en) Method and means for producing tissues and tissues obtained
EP4215185A8 (en) Method for bowel preparation
WO2011078475A3 (en) Dental implant having plate
EP2316941A3 (en) Compositions and their uses directed to IL-4R alpha
MX2009012510A (en) Coating of implants with hyaluronic acid solution.
ATE547110T1 (en) USE OF CELLS FROM FAT TISSUE TO PRODUCE AN ANTITUMORAL DRUG
WO2022170134A3 (en) Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof
TW200507832A (en) Composition for normalization of infradian rhythm
CA2837895C (en) Methods of treating or preventing neurological diseases
EP4389218A3 (en) Composition for treating joint disease and kit containing same
NO20082672L (en) Use of cycletanine and other fluoropyridines for the treatment of systolic-dominant hypertension, isolated hypertension, increased pulse pressure and general hypertension
CA3168207A1 (en) Cellular uptake
MX2009006670A (en) Pharmaceutical composition using aliskiren and avosentan.
WO2009134396A3 (en) Use of corticotropin-releasing factor for the treatment of cancer
PL433516A1 (en) Biological implant and method of obtaining it
UA42793U (en) Method for treatment of patients suffering from lambliasis